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  Treatment of Rheumatoid Arthritis with Marine and Botanical Oils:  Influence on Serum Lipids 
 
Barbara Olendzki , RD, MPH; Katherine Leung, MPH, Susan Van Buskirk,  M.Ed., CCRC, George Reed, PhD, and Robert B. Zurier, MD   
Division of Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, MA 
                                                                                                                  
BACKGROUND 
Over the past 30 years substantial progress has been made in the medical and surgical 
management of patients with rheumatoid arthritis (RA).  Despite this progress, there is an 
increasing gap in mortality between patients with RA (1.5-3.0 fold risk) and the general 
population. This disparity is mainly attributable to cardiovascular disease (CVD) as the 
CVD risk is comparable in RA patients as to patients with diabetes mellitus.  Although the 
reasons for this gap are not entirely clear, the traditional risk of abnormalities in lipid 
profiles appears to be enhanced by a chronic increase in inflammatory cytokines, resulting 
in accelerated atherosclerosis.  
Study Objective 
 
The object of this study was to determine the effect of marine (fish oil) and botanical oils 
(borage oil) on lipids (TC, HDL, LDL, TG), a risk factor for cardiovascular disease in 
patients with RA.  The main outcome (to be presented elsewhere) was to determine 
whether a combination of borage seed oil rich in gammalinolenic acid (GLA) and fish oil 
rich in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is superior to either 
oil alone for the treatment of RA. 
METHODS 
RESULTS 
DISCUSSION 
Baseline Mean (SD) 
(N=145) 
Change from Baseline 
to 9 months (N=83) 
Change from Baseline 
to 18 months (N=69) 
Total cholesterol 195.77 (37.48)  -3.45 
(-7.88 to 0.98) 
-8.43* 
(-12.99 to -3.86) 
LDL 114.63 (32.20) -4.39** 
 (-8.03 to -0.74) 
-9.43* 
 (-13.75 to -5.11) 
HDL 54.14 (16.21) 3.96* 
(2.44 to 5.49) 
5.02* 
 (3.24 to 6.81) 
TC/HDL ratio† 3.83 (1.03) -0.26*  
(-0.41 to -0.12) 
-0.43* 
(-0.58 to -0.28) 
Triglyceride † 138.05 (79.65)   -21.96 * 
(-30.52 to -13.40) 
-24.42*  
(-33.22 to -15.61) 
Atherogenic Index of 
Plasma 
0.84 (0.67) -0.22 * 
(-0.29 to -0.16) 
-0.26* 
(-0.33 to -0.19) 
 Serum Lipids Results 
 Rheumatoid Arthritis (RA) is a chronic systemic inflammatory disease. Mediators of inflammation and prothrombotic factors 
contribute to endothelial dysfunction and development of cardiovascular disease in RA patients. Marine and botanical oils represent 
an excellent primary or secondary therapy for improvement of the cardiovascular risk management in RA. 
 
Patients taking these oils exhibit significant additional reductions in total and LDL-cholesterol, triglycerides, the TC/HDL ratio, and in 
the atherogenic index, and experience a significant increase in HDL-cholesterol. All of these improvements in the lipid profile were 
seen after 9 months of therapy, and increased after 18 months of oils administration. 
 
The overall dropout rate was 51%, and was similar across groups: 25 in the borage oil group, 28 in the fish oil group, and 22 in the 
combination group.  Reasons for dropout were mainly gastrointestinal distress (belching, bloating, diarrhea, nausea, cramping), or an 
inability to swallow the large number of rather sizable capsules.  This can be ameliorated by freezing the capsules and reducing their 
size. Among those evaluated for this study, compliance was 100%, assessed by pill counts. 
Learning Outcome: 
All treatments were safe, thus treatment of RA patients with one or a combination of these or similar oils should prove useful for 
reduction of cardiovascular risk in RA patients. 
Population and Setting 
• The study was an 18 month randomized, double-
masked comparison of borage seed oil, fish oil, and 
the combination of both oils in RA patients with 
active synovitis. 
•The protocol  was approved by the Committee for 
the Protection of Human Subjects in Research at 
the University of Massachusetts Medical School and 
by the Food and Drug Administration.  Subsequent 
approvals were obtained from Review Boards at the 
University of Alabama, Geisenger Clinic, Fallon 
Health Care, and the New England IRB.  
 
Eligibility /Demographics for the RCT 
•Patients were eligible to participate in the study if 
they had RA according to the 1987 criteria of the 
American Rheumatism Association, were in 
functional class I, II, or III according to the revised 
criteria of the American College of Rheumatology, 
and were between the ages of 18 and 85.    
•The mean age of participants was 59 years, and 
the sample predominantly female (80%).  Most were 
white (90%), married (69%), and had a mean body 
mass index (BMI) of 30.5. An equal number were 
retired (33%) or working full time (34%), and 16% 
listed themselves as disabled. There were no 
significant differences between groups. 
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Intervention:  Patients received 3.5 gm omega-3 
fatty acids daily in a 2.1gm EPA/1.4 gm DHA ratio (7 
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Measurements  
Laboratory Measures: 
Lipid profile:  Fasting triglycerides, cholesterol, HDL 
and calculated LDL cholesterol, complete blood cell 
count (CBC), platelet count, ESR, albumin, creatinine, 
AST, ALT, total bilirubin.  
 
Anthropometric Measures: 
Height and weight; calculated body mass index  (BMI) 
Systolic and diastolic blood pressure (SBP, DBP) 
 
Survey Measures: 
Diet: assessed by 24-hour dietary assessment calls 
(24HR), performed at baseline and 18 months. 
Demographics:  Age, gender, education, income, 
medications, and the modified disease activity score 
(DAS 28); and Clinical Disease Activity Index (CDAI) 
were also collected. 
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Analysis 
 
To assess the effect of the intervention on lipids, lipid values were modeled using linear mixed 
modeling as a function of time (baseline, 9 month and 18 month, or final visit treated as a categorical 
variable to allow for non-linear trajectories), treatment arm, and their interaction, with adjustment for 
baseline value. To assess the overall changes over time, outcome measures were modeled using 
linear mixed modeling as a function of time, treatment arm and with adjustment for baseline value. 
All analyses were intention to treat. Analyses included all participants with a baseline lipid measure. 
Combination 
Group 
β (95%CI) 
Fish Oil 
Group 
β (95%CI) 
Borage Oil 
Group 
β (95%CI) 
p-
value 
Triglyceride ** 0.031 
     9 months -30.81  
(-46.58 to -15.03) 
-20.50  
(-35.16 to -5.85) 
-16.57 
 (-30.86 to -2.27) 
     18 months -38.24 
 (-54.28 to -22.19) 
-15.27 
 (-29.81 to -0.74) 
-22.10  
(-37.32 to -6.89) 
AIP 0.011 
     9 months -0.33 
 (-0.45 to -0.20) 
-0.20 
 (-0.32 to -0.08) 
-0.17  
(-0.33 to 0.002) 
     18 months -0.45  
(-0.57 to -0.32) 
-0.16 
 (-0.28 to -0.05) 
-0.21 
 (-0.33 to -0.09) 
 Triglycerides and Atherogenic Index of Plasma (AIP) 
by Group 
** P-value is from log transformation.  Changes shown are from 
the original scale for the group x time interaction and control for 
baseline values.  Values are presented as regression coefficient 
(95% CI). 
 
Weight 0.52 
(-1.41 to 2.46) 
0.35 
(-2.43 to 3.14) 
Systolic blood pressure 1.77 
(-0.66 to 4.20) 
-0.24 
(-3.37 to 2.90) 
Diastolic blood pressure 2.32* 
(0.56 to 4.09) 
1.88** 
(-0.003 to 3.79) 
ESR† -5.39* 
(-9.71 to -1.07) 
-4.42** 
(-9.22 to 0.38) 
CRP† -0.65* 
(-1.20 to -0.10) 
-0.09 
(-0.77 to 0.60) 
Values are presented as regression coefficient (95% CI) unless stated otherwise 
and control for baseline values.  * p <0.001 ** p<=0.05 † P-values are from log-
transformed data. 
 
Change from Baseline for Other Measurements 
 Change at 9 months: 
β (95%CI) 
Change at 18months: 
β (95%CI) 
